Company Overview and Class Action Context

Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company focused on rare diseases. Its lead (and only) product, VYKAT™ XR (diazoxide choline extended-release tablets), was approved by the FDA on March 26, 2025 as the first treatment for hyperphagia (insatiable appetite) in Prader–Willi syndrome (PWS) (www.globenewswire.com) (www.fiercepharma.com). The drug (formerly known as DCCR) addresses a critical unmet need in PWS, a disorder affecting roughly 1 in 15,000 births (about 10,000 patients in the U.S. and 300,000 globally) (www.fiercepharma.com). Soleno launched VYKAT XR in April 2025, and initial uptake was strong – by mid-2025 over 600 patient start forms and nearly 300 prescribers were on board (soleno.gcs-web.com) (soleno.gcs-web.com). However, the company now faces legal headwinds: multiple law firms have filed a securities fraud class action alleging Soleno misled investors about VYKAT XR’s safety profile. Shareholders who purchased SLNO between March 26, 2025 and November 4, 2025 (the class period) have until May 5, 2026 to seek lead-plaintiff status (www.prnewswire.com) (www.prnewswire.com). The lawsuit claims Soleno made “material misstatements and/or omissions” regarding its Phase 3 trials – specifically downplaying evidence of potential safety issues (notably, excessive fluid retention in patients) – which made the drug seem safer and more commercially viable than it truly was (www.stocktitan.net). These allegations gained traction after Scorpion Capital, a short-selling firm, published a critical report on August 15, 2025 raising serious safety concerns (za.investing.com). Scorpion’s report claimed there was a “rapid pile-up of reports of children hospitalized for potential heart failure” shortly after starting VYKAT XR, and warned the drug might even face withdrawal or a sharp drop in new prescriptions (za.investing.com). Soleno’s stock fell about 13% that day (za.investing.com), and the PWS community grew alarmed. In its Q3 2025 update, Soleno acknowledged that the short-seller’s report caused a “disruption” in VYKAT XR’s launch trajectory and concerns within the PWS community (www.prnewswire.com). The class action now pending (e.g. City of Pontiac Police & Fire Retirement System v. Soleno Therapeutics, Inc.) is centered on whether Soleno’s management failed to fully disclose those safety issues in a timely manner (www.stocktitan.net). This legal cloud, and an upcoming May 5, 2026 deadline for affected investors to act, form the backdrop of an otherwise remarkable story of a small biotech delivering an FDA-approved therapy and reaching profitability within its first commercial year.

Dividend Policy and Shareholder Returns

Soleno has never paid any cash dividend on its common stock and does not anticipate doing so in the foreseeable future (www.sec.gov) (www.sec.gov). Like many growth-oriented biotech companies, it reinvests earnings into development and commercialization rather than returning cash to shareholders. In fact, Soleno’s loan covenants prohibit paying dividends or other distributions – a typical restriction until debt is repaid (www.sec.gov). Investors in SLNO therefore rely entirely on stock price appreciation for returns, not dividend yield. Despite the lack of dividends, Soleno found an alternate way to return value: after its drug launch success, the company authorized a large share repurchase. In November 2025, Soleno announced a $100 million accelerated share repurchase (ASR) program (www.globenewswire.com) – an unusual move for a biotech at this stage. Management used some of the company’s abundant cash (see below) to buy back stock, signaling confidence in Soleno’s prospects and perhaps an effort to support the share price, which had been under pressure. This ASR was completed by year-end 2025, reducing share count and effectively delivering capital back to shareholders (www.globenewswire.com). Still, no direct dividends are expected, consistent with the company’s stated policy of retaining earnings for growth (www.sec.gov).

(AFFO/FFO metrics are not applicable here, as Soleno is not a REIT or cash-flow real estate firm but a biotech. Instead, traditional earnings and cash flow metrics gauge its financial performance.)

Financial Performance and Valuation

Soleno’s financial turnaround in 2025 was striking. The FDA approval of VYKAT XR in March 2025 transformed the company from a pre-revenue R&D outfit into a revenue-generating, profitable enterprise by Q3. In the nine months of commercial sales (April–Dec 2025), Soleno generated $190.4 million in net product revenue (www.globenewswire.com). Quarterly sales ramped rapidly: $32.7 million in Q2 (the first full quarter of launch), then $66.0 million in Q3, and $91.7 million in Q4 2025 (www.globenewswire.com) (www.globenewswire.com). These sales drove improving profitability. After years of losses, Soleno achieved positive net income of $26.0 million in Q3 alone (www.globenewswire.com), and $20.9 million for full-year 2025 (www.globenewswire.com) – a notable milestone. Management attributed Q3’s strong results to “growing awareness of [VYKAT XR’s] compelling efficacy and safety profile” and its status as the only approved therapy for PWS hyperphagia (www.globenewswire.com). By year-end, approximately 859 patients were on VYKAT XR (about 12% of the U.S. PWS market, by the company’s estimate) (www.globenewswire.com) (www.globenewswire.com), indicating significant room for growth as penetration increases.

From a valuation perspective, SLNO’s stock price reflects high expectations for continued growth. As of late 2025, the stock traded around $50 per share (finance.yahoo.com). With roughly ~50–53 million shares outstanding after the mid-2025 equity raise and buyback (up from 45.9 million in Feb 2025) (www.sec.gov) (www.sec.gov), Soleno’s market capitalization stands near $2.5–2.7 billion. Subtracting the company’s large cash reserves (over half a billion dollars) and modest debt (see next section) yields an enterprise value around $2.0–2.1 billion. That equates to roughly 10–11× Soleno’s 2025 revenue, a rich EV/Sales multiple for a single-product pharma. On an earnings basis, the stock’s trailing P/E is triple-digits (over 120× the 2025 EPS of ~$0.40) – however, this reflects only the initial ramp year of earnings (www.globenewswire.com). Investors are effectively pricing in rapid earnings growth as VYKAT XR adoption widens and operating leverage improves. For context, PWS is a rare but severe disease; if Soleno eventually treats a few thousand U.S. patients (out of 10,000+), annual sales could approach $1 billion (given orphan drug pricing) – which would bring the valuation multiples down substantially. Nevertheless, the current valuation assumes smooth execution and sustained demand, leaving little margin for setbacks. It’s worth noting that despite posting profitable results, Soleno’s stock did not rally; in fact, shares dropped ~7% on the day the company announced its first full-year profits and strong revenues (www.stocktitan.net). This suggests that legal uncertainties and safety worries (discussed below) are weighing on sentiment, tempering the fundamental optimism.

Leverage, Debt Maturities, and Coverage

Soleno’s balance sheet is robust after the 2025 commercial launch and equity raise. The company ended 2025 with $506.1 million in cash, equivalents and marketable securities (www.globenewswire.com), thanks to both revenue inflows and financing. In July 2025, Soleno bolstered its coffers with a public stock offering of ~2.7 million shares at $85 each, raising $230 million in gross proceeds (soleno.gcs-web.com) (www.sec.gov). It also likely received a Priority Review Voucher (PRV) upon VYKAT XR’s approval (common for rare pediatric disease approvals), though any sale of a PRV has not been explicitly reported. On the debt side, Soleno has a single significant borrowing: a loan facility with Oxford Finance LLC established in December 2024. Under that agreement, Soleno drew $50 million initially, with additional tranches available upon achieving milestones (www.sec.gov) (www.sec.gov). As of Q3 2025, $50 million remained outstanding under this term loan (www.sec.gov). The debt’s terms are favorable: interest-only payments for 48 months and a total maturity of 60 months (extended by 12 months if certain sales/regulatory milestones are met by Sept 2026) (www.sec.gov). In effect, no principal repayment is due until roughly late 2028 (or 2029 if extended), giving Soleno ample breathing room. The interest rate is floating (1-month SOFR + 5.5%) (www.sec.gov), which currently equates to around ~10% annually – a manageable cost given the company’s cash generation. In 2025, Soleno’s interest expense was about $4–5 million (annualized) (www.sec.gov), a trivial amount relative to its $190 million revenue and $49 million Q4 operating cash flow (www.globenewswire.com) (www.globenewswire.com). Interest coverage is therefore very strong: even in Q4 alone, Soleno’s operating cash flow (nearly $49 million) could cover the entire year’s interest many times over (www.globenewswire.com). With net cash well above $450 million, Soleno’s leverage is low and its liquidity position is excellent. The sizable cash reserve not only secures the company’s runway for further expansion (and any legal costs), but also enabled the aforementioned $100 million share buyback without jeopardizing financial stability (www.globenewswire.com). Looking ahead, Soleno has access to more debt if needed ($25 million became available in Oct 2025, and an additional $50 million with lender consent) (www.sec.gov), though it may not need to draw these given its cash-rich status. Overall, debt maturities are distant and well-covered by cash, and there are no liquidity red flags on the horizon from a balance sheet perspective.

(“Coverage” in terms of fixed charges or AFFO is not a typical metric for a biotech, but Soleno’s interest coverage and cash flow coverage of expenses are very healthy given its profitability and cash reserves.)

Key Risks

Despite Soleno’s operational success, investors face several key risks:

– Single-Product Dependence: Soleno is essentially a one-product company, wholly reliant on VYKAT XR (DCCR) for its revenue and growth (www.sec.gov). The company “is dependent upon the success of DCCR, [its] sole therapeutic product” (www.sec.gov), as management openly acknowledges. Any setback to this product – whether clinical, regulatory, or commercial – would have an outsized impact. The PWS market itself is finite (estimated ~10k U.S. patients), so Soleno’s fortunes hinge on maximizing penetration and maybe expanding the drug’s label. The lack of other approved products or a diverse pipeline leaves Soleno with no cushion if VYKAT XR’s trajectory falters.

– Safety and Efficacy Concerns: The safety profile of VYKAT XR is under intense scrutiny. While the drug showed efficacy in reducing hyperphagia in trials, adverse reactions like edema (fluid retention) and hyperglycemia occurred in roughly 10% of patients in long-term studies (www.fiercepharma.com). These were characterized as mostly mild or manageable. However, reports of more severe outcomes have emerged in the post-market setting: as noted, a short-seller alleged cases of heart failure in children after starting the drug (za.investing.com). Soleno insists the adverse events are “on-label” and largely non-serious (e.g. “mild peripheral edema, some hyperglycemia” causing some patients to discontinue) (www.ainvest.com) (www.ainvest.com). Indeed, by Q3 2025 about one-third of patients had dropped off within ~3 months of initiation, often due to these side effects, though two-thirds remained beyond 3 months on therapy (www.ainvest.com) (www.ainvest.com). The risk is that if a significant safety issue is confirmed – for example, if edema-related cardiac events are more common than disclosed – regulators could intervene (label warnings, risk evaluation requirements, or in extreme cases, suspension of marketing). Even absent FDA action, physician and caregiver perception of safety can affect uptake. Soleno observed a slowdown in new patient starts and more drop-offs in Aug–Sep 2025 coinciding with the safety scare (www.ainvest.com) (www.ainvest.com). Although October trends normalized somewhat (www.ainvest.com) (www.ainvest.com), rebuilding confidence is crucial. Bottom line: Soleno must demonstrate that VYKAT XR’s benefits clearly outweigh its risks in a fragile patient population. Any future serious adverse events or negative study could severely hurt adoption and bring litigation or regulatory consequences.

– Regulatory and Commercial Execution: Soleno is navigating its first drug launch, and execution risks remain. The company must continue to secure broad insurance coverage (185 million U.S. covered lives were achieved by year-end 2025) (www.globenewswire.com) and integrate feedback from the medical community to drive prescriptions. Managing dosage and side effects (e.g. mitigating edema via dose titration or diuretics) is a key part of ensuring long-term therapy persistence. With European approval efforts underway (an EU marketing application was submitted in mid-2025) (soleno.gcs-web.com), Soleno faces the challenge of expanding internationally, likely requiring partnerships or added infrastructure. The EMA may scrutinize safety closely; a delay or denial in Europe would slow Soleno’s global expansion plans. Manufacturing is another risk – as a small company, Soleno relies on sole-source suppliers for the drug and its components (www.sec.gov), so any production hiccup or quality issue at a single supplier could disrupt supply (www.sec.gov). Additionally, while no competitor drug is approved for PWS hyperphagia (several attempts by others have failed) (www.fiercepharma.com), competition could emerge. Future therapies (e.g. hormonal or genetic treatments) are being researched. Soleno’s patents for DCCR begin expiring in 2025–2026 (though others extend to 2035) (www.sec.gov), and the drug has 7-year orphan exclusivity (until 2032) in the U.S. – a decent market exclusivity window, but not insurmountable. If a rival finds a safer or more convenient solution, or if generic diazoxide formulations aim to compete after exclusivity, Soleno could face challenges defending its market share (za.investing.com).

– Financial and Market Risks: Although currently well-funded, Soleno’s cash burn for commercialization and any new R&D could rise. Launching in new territories, conducting additional trials (the company plans to test DCCR in other rare disorders), and potential legal settlements all cost money. The company’s decision to spend $100 million on share buybacks reflects confidence but also removes cash that could have funded pipeline development. If revenue growth disappoints or costs increase, Soleno might eventually need to raise capital again (diluting shareholders) or tap more debt, especially once it ventures beyond PWS. Market risk is evident in the stock’s volatility – positive news hasn’t guaranteed price gains. The overlay of legal concerns has made the stock’s performance disconnect from fundamentals at times (www.stocktitan.net). This volatility can itself be a risk for equity holders, especially around key events (trial readouts, lawsuit updates, etc.). Furthermore, insider actions bear watching: the short report pointed out insiders sold shares soon after FDA approval (implying some took profits at highs) (mobile.twstalker.com), which if true could be viewed negatively (though such sales may have been pre-planned). Lastly, the ongoing class action litigation could result in costs or distractions – while damages or settlements would likely be covered by insurance in part, a protracted legal battle could still siphon management attention and weigh on the stock’s reputation.

Red Flags and Controversies

Several red flags have emerged in the SLNO story:

– Securities Class Action & Alleged Misconduct: The very need for an “urgent class action deadline” warning is a red flag in itself. The class action lawsuits (filed by firms like Kessler Topaz and Kahn Swick & Foti) indicate that reputable securities litigators see potential merit in claims of misleading statements by Soleno (www.prnewswire.com) (www.stocktitan.net). The allegations focus on whether Soleno knew more about DCCR’s safety issues than it disclosed to investors during the pivotal launch period. For example, if internal data or early post-approval reports showed significant edema or cardiac side effects, any failure to communicate that promptly (especially while executives were touting a “favorable safety profile” (www.globenewswire.com) and selling stock) could be deemed a material omission. The resignation/retirement of the CFO in Q1 2026 adds to this cloud – though described as a planned retirement, it happened as lawsuits ramped up (app.researchpool.com). The new CFO hired (Jennifer Fulk, a veteran from Eli Lilly) brings experience, but sudden C-suite turnover amid controversy can be interpreted cautiously. It’s important to stress these are allegations at this stage; no findings of wrongdoing have been made. Yet the presence of multiple law firm investigations (Faruqi & Faruqi, Hagens Berman, Gibbs Law, Robbins Geller, etc., alongside Kessler and KSF) (intellectia.ai) (hk.marketscreener.com) highlights that Soleno is under the microscope. This overhang will persist until the case is resolved, and it suggests heightened governance risk – investors must trust that management is being fully transparent going forward.

– Short-Seller Accusations: The Scorpion Capital short report from August 2025 is another red flag that can’t be ignored. Scorpion has a track record of aggressive short campaigns, and in Soleno’s case they painted a dire picture – calling the company a “one-trick pony” with “no meaningful pipeline” and claiming VYKAT XR is essentially an old drug repackaged (diazoxide has been used for other purposes for decades) (za.investing.com). They pointed out that one of Soleno’s PWS drug predecessors, Zafgen, suffered fatal outcomes in trials and collapsed, insinuating Soleno might face a similar fate (za.investing.com). Perhaps most alarming, Scorpion alleged multiple recent hospitalizations for heart failure among patients, implying Soleno’s drug could be far riskier than publicly known (za.investing.com). Soleno has not publicly refuted specific claims in detail (no direct response press release was issued, which some companies do to counter shorts). Instead, management implicitly addressed it in conference calls by acknowledging an uptick in discontinuations and pledging to educate physicians on managing side effects (www.ainvest.com) (www.ainvest.com). The lack of a strong rebuttal leaves some questions. In any case, the short report succeeded in driving the stock down and seeding doubt. The fact that Soleno’s share price remains vulnerable to legal and negative headlines – with drops on each lawsuit announcement (www.stocktitan.net) – suggests that where there’s smoke, the market fears fire. Investors should consider the short-seller’s points: Soleno is a one-product company (true), with an old compound (diazoxide) at its core (true, though reformulated and repurposed), facing known side effects (edema, etc., also true). While the “heart failure” claims are unconfirmed, they underscore the need for vigilance. This controversy is a red flag primarily because it shows a trust deficit – some stakeholders question management’s candor and the drug’s true risk/benefit profile.

– Unusual Shareholder Moves: Soleno’s decision to execute a massive buyback so early in commercialization, as mentioned, is atypical. Returning $100 million to shareholders via repurchases – rather than conserving it for pipeline or contingencies – could be seen as a vote of confidence by the board. However, skeptics might frame it as financial engineering to buoy the stock price during turbulent times (especially since it was announced in Nov 2025, shortly after the short attack and amid lawsuits). If the motive was to counteract share price weakness or to placate restive investors, that’s somewhat concerning, as it diverts cash that might be needed if any issue arises. Another point: the stock offering in mid-2025 at $85/share, followed weeks later by a short report-induced crash to much lower levels, meant new investors took an immediate hit. It’s not uncommon for biotechs to raise capital after good news, but the timing looks unfortunate in hindsight – did insiders foresee any storm? Also, references to Form 144 filings around the FDA approval date indicate insiders were planning stock sales when enthusiasm was high (mobile.twstalker.com). Significant insider selling soon after a pivotal event can be a red flag if it suggests they thought the stock was fully valued. While executives are entitled to take profit (and these could have been pre-scheduled trades), it’s something to monitor in proxy filings.

– Market Behavior: A subtle red flag is how the market has reacted to Soleno’s news flow. Ideally, a biotech that wins FDA approval and turns profitable in under a year would be a market darling. Yet Soleno’s stock performance has been dampened. As noted, even outstanding Q4 earnings and a rosy launch update in Feb 2026 saw the stock fall ~7% (www.stocktitan.net). This suggests that investor confidence is shaky – many may be waiting for the other shoe to drop regarding the lawsuits or further safety revelations. The stock is still well below its 2025 highs (it was $80+ in July 2025 during the equity raise), indicating that the controversies have eroded a lot of the initial euphoria. Such skepticism among investors can be self-reinforcing: it may pressure management to overdeliver or take on extra measures (like the buyback) to regain trust. In summary, while Soleno has a legitimate breakthrough drug and solid financials, these red flags emphasize that perception of the company has been marred by credibility questions. New investors should tread carefully and do thorough due diligence on these issues.

Open Questions and Outlook

As Soleno navigates 2026 and beyond, several open questions remain:

– How will the class action resolve, and what will be uncovered? The outcome of the ongoing securities litigation is uncertain. A best-case scenario for Soleno might be a quick dismissal or a modest settlement that puts the issue to rest; a worst-case could involve protracted discovery that reveals internal documents indicating the company knew more about safety problems (which could not only lead to larger liability but also damage management’s reputation or even prompt regulatory review). Investors should watch for any updates from the court case – for example, if a lead plaintiff (like the Pontiac pension fund) produces strong evidence of omitted safety data or misleading statements, it could be a game-changer. Conversely, if the case is weak, it may quietly settle with the company not admitting wrongdoing. The May 5, 2026 lead plaintiff deadline is just the start; what follows could influence Soleno’s governance (perhaps prompting changes or improved disclosures). This question ties into a broader one: can management restore full confidence? Bringing in a seasoned CFO and maintaining transparency in future reports will be key. Any indication that Soleno is proactively addressing safety (publishing detailed safety updates, etc.) would help, whereas evasiveness could hurt.

– Will VYKAT XR’s safety profile hold up in the real world? This is arguably the most critical question for the business. Now that over 800 patients have been on therapy and the number will grow, will new risks emerge? The first year of post-approval use gave some hints – e.g., higher drop-out rates early on due to side effects (www.ainvest.com) (www.ainvest.com). What about rare events? For instance, was the “heart failure” alarm a false signal or a real but rare complication? The company will likely provide updates on adverse events in conference calls or scientific meetings. Investors will want to see if discontinuation rates improve as doctors gain experience (Soleno said most discontinuations happened in the first 3 months and “restart rates” were low so far (www.ainvest.com) (www.ainvest.com)). An open question is whether mitigation strategies (like slower titration, better patient screening for risk factors, or adjunct treatments to manage side effects) can reduce serious adverse outcomes. Also, will the FDA require any post-marketing studies or labeling changes? Thus far, no FDA alerts have been issued publicly, but continued vigilance is necessary. If VYKAT XR’s safety holds steady (no new major concerns), it will bolster long-term adoption; if not, usage could plateau or decline.

– How fast and deep can Soleno penetrate the PWS market? After 9 months, about 12% of the addressable U.S. patients were in process (1,250 start forms, 859 still active by Dec 2025) (www.globenewswire.com) (www.globenewswire.com). The trajectory of growth is an open question. Did the short-seller controversy merely delay some patients (with growth resuming later), or did it permanently limit the pool of willing prescribers? Management in February 2026 remained upbeat, noting a “positive trajectory” in leading indicators like new prescribers and covered lives (www.globenewswire.com). One question is how quickly Soleno can convert the remaining untapped patients. Are there barriers such as diagnosing all patients, reaching geographically dispersed families, or reluctance of some physicians? The company’s commercial team had a strong initial push; sustaining that momentum into a second wave of adoption will be telling. Moreover, pricing and reimbursement in subsequent years could affect uptake. Orphan drug launches often face pushback from payers over cost. Soleno reported over 185 million insurance lives covered by end of 2025 (www.globenewswire.com), which is good, but it’s unclear if any utilization management (like prior authorizations or step therapy) could slow access. Another factor: will competitors or off-label approaches creep in? For example, could some doctors try alternative appetite-suppressing drugs (even off-label) for PWS if they perceive safety advantages? While no direct competitor exists now, staying ahead on efficacy and safety will determine if Soleno captures the majority of the 10,000 patients or significantly less.

– What is the plan for growth beyond PWS? Soleno’s management has hinted at leveraging diazoxide choline in other high-need rare diseases (www.globenewswire.com). Indeed, their patent portfolio includes method claims for conditions like Smith-Magenis Syndrome (SMS) (www.sec.gov), another rare disorder with metabolic components. An open question is: Can DCCR (VYKAT XR) show benefit in other indications? If yes, that could expand the market substantially and provide diversification. For instance, if a trial in SMS or another syndrome shows positive results, Soleno could pursue additional approvals. However, development in new indications would take time and money, and there’s no guarantee of success. Investors should watch for any announcements of new clinical programs. Until then, Soleno remains a one-product story, so this question is about the long-term vision. Additionally, how will Soleno approach markets outside the U.S.? The European Medicines Agency (EMA) decision is pending (the application was validated in mid-2025) (soleno.gcs-web.com). If EU approval comes, launching in Europe poses questions: will Soleno commercialize directly in key countries or seek a partner? The outcome in Europe (and other regions like Japan) will influence the total addressable patient pool the company can serve. It’s also worth asking if Soleno intends to partner or be acquired. Larger pharma companies might be interested in a first-in-class PWS therapy if the risk profile stabilizes. Soleno’s current cash suggests it doesn’t need a partner financially, but a bigger commercial platform could accelerate uptake globally. Management hasn’t indicated any near-term M&A plans, but as the company matures, this could become a strategic question.

– Is the stock’s risk/reward profile attractive now? For investors, an open-ended consideration is whether SLNO’s current price appropriately balances its promise against its perils. At ~$50/share, the stock prices in significant growth and successful issue resolution. The upside questions: Could the company beat expectations by, say, reaching 50% of U.S. patients (bringing multi-hundred-million revenue annually) and expanding overseas, thereby justifying a multi-billion valuation or even higher? Could it develop a second product or indication that adds value? The downside questions: What if safety concerns limit uptake to, say, only 20–30% of patients long-term? What if legal/regulatory hiccups slow expansion or result in fines/penalties? These scenarios will play out over the next 1–2 years. In the interim, the stock may remain volatile. Notably, Soleno’s share price weakness in early 2026 (despite good earnings) suggests many investors are in “wait-and-see” mode (www.stocktitan.net). If one or more open questions get answered favorably – e.g., lawsuit resolved, EU approval gained, no new safety issues in 2026 – the stock could re-rate higher. If the opposite occurs, it could retrench.

In summary, Soleno Therapeutics has tremendous potential as a pioneer in a rare disease with no prior treatments, and it has proven it can execute by rapidly achieving profitability (www.globenewswire.com). Yet, the road ahead has critical uncertainties. Investors must monitor the evolving story: legal outcomes, real-world safety data, market penetration trends, and strategic moves will determine if SLNO’s early promise translates into sustainable long-term success or if obstacles will temper its trajectory. As the May 5, 2026 class action deadline approaches, all eyes are on how Soleno’s management addresses the concerns raised and whether they can keep the trust of both patients and shareholders in this delicate phase of growth (www.stocktitan.net).

For informational purposes only; not investment advice.